Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cncr.23135PMID 17999418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

  2005cited by this paper
• Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines.

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Oesophageal cancer incidence and mortality in patients with long-segment Barrett's Oesophagus after a mean follow-up of 12.7 years

  2004influential reference
• World Cancer Report

  2003cited by this paper
• Gene silencing in cancer in association with promoter hypermethylation.

  2003cited by this paper
• Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study

  2003influential reference
• N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells.

  2002cited by this paper
• Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus

  2002influential reference
• Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas.

  2002cited by this paper
• Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.

  2001cited by this paper
• Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

  2001cited by this paper
• Somatostatin, Its Receptors and Analogs, in Lung Cancer

  2001cited by this paper
• Lipophilization of somatostatin analog RC‐160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro

  2000cited by this paper
• The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression

  2000influential reference
• Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus

  2000cited by this paper
• Roles of Cell Division and Gene Transcription in the Methylation of CpG Islands

  1999cited by this paper
• Somatostatin and its receptor family.

  1999cited by this paper
• Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.

  1999cited by this paper
• Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus

  1998cited by this paper
• Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus.

  1997influential reference
• Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.

  1997cited by this paper
• Somatostatin analogs for diagnosis and treatment of cancer.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• International Agency for Research on Cancer.

  1985cited by this paper
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper
• Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

  1973cited by this paper
• GASTROENTEROLOGY 2006;131:797–808 BASIC–ALIMENTARY TRACT A Genome-Wide Search Identifies Epigenetic Silencing of Somatostatin,

  year unknowninfluential reference

• Associations Between Non-Genetic Risk Factors and DNA Methylation Alterations in Barrett’s Esophagus and Its Progression to Esophageal Adenocarcinoma

  2025cites this paper
• Discovery of Methylated DNA Biomarkers for Potential Non-Endoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.

  2025cites this paper
• Molecular Abnormalities and Carcinogenesis in Barrett’s Esophagus: Implications for Cancer Treatment and Prevention

  2025cites this paper
• Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma and its Clinical Implications in Systemic Chemotherapy

  2025cites this paper
• DNA methylation in esophageal cancer: technological advances and early detection clinical applications

  2025influential citation
• The utility of a genetic progression risk test for Barrett esophagus

  2022cites this paper
• Site-Specific Hypermethylation of SST 1stExon as a Biomarker for Predicting the Risk of Gastrointestinal Tract Cancers

  2022cites this paper
• Constitutive programmed death ligand 1 expression protects gastric G‐cells from Helicobacter pylori–induced inflammation

  2022cites this paper
• Age-related DNA methylation in paired normal and tumour breast tissue in Chinese breast cancer patients

  2020cites this paper
• SST gene hypermethylation acts as a pan‐cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood‐based diagnosis

  2020cites this paper
• Time series expression pattern of key genes reveals the molecular process of esophageal cancer

  2020cites this paper
• Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer

  2020cites this paper
• Regulatory Mechanisms of Somatostatin Expression

  2020influential citation
• Comprehensive multi-omics analysis identified core molecular processes in esophageal cancer and revealed GNGT2 as a potential prognostic marker

  2019cites this paper
• Evaluation of Ficolin-3 as a Potential Prognostic Serum Biomarker in Chinese Patients with Esophageal Cancer

  2019cites this paper
• Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study

  2019cites this paper
• Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer

  2018cites this paper
• Neuroendocrine Factors and Head and Neck Squamous Cell Carcinoma: An Affair to Remember

  2018cites this paper
• The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

  2018cites this paper
• Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells

  2018cites this paper
• ChApTEr 4 Genome-wide DNA methylation profiling reveals methylation markers associated with 3 q gain for detection of cervical precancer and cancer

  2018cites this paper
• Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer

  2018influential citation
• Neuroendocrine factors: The missing link in non-melanoma skin cancer

  2017cites this paper
• Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer

  2017cites this paper
• Epigenetics in Obesity and Esophageal Cancer

  2016cites this paper
• Methylation of serum SST gene is an independent prognostic marker in colorectal cancer.

  2016cites this paper
• Genetics and Biomarkers in Barrett’s Esophagus and Esophageal Adenocarcinoma

  2016cites this paper
• Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma

  2016cites this paper
• Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data

  2015cites this paper
• Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.

  2015cites this paper
• Promoter Hypermethylation-Related Reduced Somatostatin Production Promotes Uncontrolled Cell Proliferation in Colorectal Cancer

  2015cites this paper
• G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?

  2015cites this paper
• Biomarkers for Dysplastic Barrett’s: Ready for Prime Time?

  2015cites this paper
• Aberrant Methylation Inactivates Somatostatin and Somatostatin Receptor Type 1 in Head and Neck Squamous Cell Carcinoma

  2015cites this paper
• Chapter 16 – Esophageal Cancer

  2015cites this paper
• Epigenetic biomarkers in esophageal cancer.

  2014cites this paper
• Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis

  2014cites this paper
• Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma

  2013cites this paper
• A review of the alterations in DNA methylation in esophageal squamous cell carcinoma

  2013cites this paper
• Ontogeny of mRNA expression of somatostatin and its receptors in chicken embryos in association with methylation status of their promoters.

  2013cites this paper
• Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer

  2013cites this paper
• Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.

  2012influential citation
• Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma

  2012cites this paper
• Review Article Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma

  2012cites this paper
• Dysplasia and early neoplasia in Barrett's oesophagus

  2012cites this paper
• Epigenetics meets endocrinology.

  2011cites this paper
• Epigenetic Alterations as Contributors to the Pathogenesis, Detection, Prognosis and Treatment of Human Pre-invasive Neoplasia

  2011cites this paper
• Epigenetic Silencing of Somatostatin in Gastric Cancer

  2010influential citation
• The value of epigenetic markers in esophageal cancer

  2010cites this paper
• Somatostatin Methylation as a Biomarker for Gastric Cancer: Ready for “Prime Time” or for Further Validation?

  2010cites this paper
• A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.

  2009cites this paper
• An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer.

  2009cites this paper
• Complete objective response of oesophageal squamocellular carcinoma to biological treatment.

  2009cites this paper
• Barrett's Esophagus and esophageal adenocarcinoma.

  2009cites this paper
• Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors

  2008cites this paper